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Integrative medicine is not only an innovative China model in clinical practice, but also the bridge for TCM toward the world.
In the past thirty years, great achievements have been made in integrative medicine researches, especially in clinical practice. The
clinical achievements mainly include the following three: innovating methodology of disease-syndrome combination, excavating
the classical theory in traditional Chinese medicine (TCM), preventing and curing refractory diseases. The development ideas and
strategies of integrative medicine for future mainly include (a) standing on frontier ﬁeld of international medicine and improving
the capability of preventing and curing refractory diseases; (b) moving prevention and control strategy forward and improving the
curativeeﬀect ofcommonandfrequentdisease;(c)excavating theclassical theoryofTCMandbroadeningthetreatmentsystemof
modern medicine; (d) improving the innovation level of new high eﬀective drugs on the basis of classical prescriptions and herbs
in TCM; (e) rerecognizing the theory of formula corresponding to syndrome in TCM and enhancing the level of clinical research
evidence based on evidence-based medicine. Integrative medicine will do obtain greater achievements in creating new medicine
and pharmacology and make more tremendous contributions for the great rejuvenation of the Chinese nation and human health
care.
1.Introduction
The coexistence of western medicine (WM) and tradi-
tional Chinese medicine (TCM) began to appear when
WM was introduced to China from the middle of 16th
century. The tendency of “conﬂuence of Chinese and
western medicine” appeared as the two medical systems
contacting and inﬂuencing with each other since then.
With the development of modern medical technology, inter-
course, and cooperation between TCM and WM, integrative
medicine was established in the 1980s. Under the guidance
of “system learning, comprehensively mastering, sorting,
and improving,” predecessors of integrative medicine have
been exploiting the complementary advantages of macro
and micro, global and local, structure and function, tradi-
tional and modern, disease diﬀerentiation, and syndrome
diﬀerentiation in WM and TCM, in order to create new
medicine and pharmacology theory. Through unremitting
eﬀorts of integrative medicine staﬀsa th o m ea n da b r o a d ,
remarkable achievements have been made in health care,
teaching, researching, academic development, discipline
construction, talent training, and so forth. So we can say that
integrative medicine is not only an innovative China model
in clinical practice, but also the bridge for TCM toward
the world [1–3]. Now the clinical achievements of the past
30 years and developing strategies of integrative medicine
are described as follows.
2. ClinicalAchievements
2.1. Innovating Methodology of Disease-Syndrome Combina-
tion: A New Mode for Syndrome Research. The relationship
between disease and syndrome is thought to be one of the
mostsigniﬁcantproblemsinTCMclinicalandbasicpractice.
As a new mode for syndrome research, disease-syndrome
combination mainly refers to absorbing the idea and theory
of disease diﬀerentiation in western medicine (WM) as2 Evidence-Based Complementary and Alternative Medicine
well as syndrome diﬀerentiation in TCM. The mode, which
originates from the medical practice since more than half a
centuryago,hasrealizedmutualcompensationofadvantages
ofTCMandWM[1,2].Combiningwholethinking,imagery
thinking, and dialectical thinking in TCM with materialism
of modern medical sciences, the mode can be regarded
as a good cut-in point and successful control pattern for
integrative medicine [3]. It has complementary advantages
of WM and TCM and marks a new era created by integrative
medicine in clinical researches. Seminar on the academician
Chen Keji’s academic thinking about “the new mode of
disease-syndrome combination and its application in clinical
practice” was held in Beijing on May 23, 2011. Professor
Chen and his students discussed the scientiﬁc connotation
of this new mode and its application in diagnosis, treatment,
and scientiﬁc research together. China news of traditional
Chinese medicine, a famous domestic media, made follow-
up report on the symposium, which had evoked large
repercussions.
Academician Chen Keji pointed out that modern view
of disease-syndrome combination includes six aspects: (a)
mode of disease diﬀerentiation by WM combined with
syndrome diﬀerentiation by TCM; (b) mode of syndrome
diﬀerentiation and treatment combined with speciﬁc pre-
scription for certain illness; (c) mode of treating according
to disease staging; (d) mode of diﬀerentiation of the basic
pathogenesis combined with syndrome diﬀerentiation and
treatment in TCM; (e) mode of treating according to
syndrome diﬀerentiation rather than disease diﬀerentiation
when there’s no disease can be diagnosed in WM; (f) mode
of treating according to disease diﬀerentiation rather than
syndrome diﬀerentiation when there’s no syndrome can be
diagnosed in TCM [4]. The emphasis of the mode could be
played on either syndrome or disease. As the connotation
of syndrome in TCM is signiﬁcantly diﬀerent from disease
in WM, laying special emphasis on syndrome means that
syndrome is just the basis of therapeutic scheme. On the
contrary, eﬀective therapeutic plans should be formulated
according to disease diﬀerentiation when special emphasis is
laid on disease. This new mode is beneﬁcial to the original
innovation in diagnosis and treatment. The advantages of
the mode include four aspects as follows. (a) Deﬁnitely
diagnosing. As the disease diagnosis in TCM is vague and
extensive, it is entirely necessary and possible to absorb
some relevant achievements of disease diagnosis in WM for
deﬁnitely diagnosing. (b) Targeted treating. As the new mode
pays more attention to the therapeutic evaluation of disease,
it could achieve more deﬁnite therapeutic targets and stable
curative eﬀect compared with syndrome diﬀerentiation
mode alone. (c) Accurately prognosing. Summarization of
clinical phenomena is the principal judgment basis for prog-
nosis in TCM, therefore, the prognosis judgment is always
not very accurate. However, the new mode has vital guidance
value for treatment and prognosis judgment. (d) Deepening
classics. Due to the succinctness and conciseness of TCM
classics, the essential features of the disease and syndrome
could be rerecognized and deepened through combining
with the modern cognition of pathology, diagnostics and
pharmacology study in WM.
Syndrome is not only the core of TCM basic theory
and syndrome diﬀerentiation, but also the bridge to asso-
ciate disease and formula. Diﬀerent from diagnosis based
on pathological mechanism, syndrome is a classiﬁcation
according to subjective symptom and objective sign collected
by physical examination [5–7]. Premise studies on disease-
syndrome combination lies in syndrome diagnostic criteria
and therapeutic evaluation system. Researches on syndrome
diagnostic criteria aim at establishing the scientiﬁc and
normative diagnosis system, while researches on therapeutic
evaluation aim at constructing an objective evaluation
system. Under the leadership of academician Chen Keji, we
are the ﬁrst to study and report on blood stasis syndrome in
coronary heart disease based on the new mode. Contributed
to the diagnosis of blood stasis syndrome in coronary heart
disease, 19 items such as precordial pain, dark purple tongue
color, and erythrocyte deformability were selected based on
the calculation analysis of 48 kinds of examination items
in 92 cases patients with coronary heart disease. And the
clinical diagnosis accordance rate was 89%. 6 items giving
the greatest contribution to diagnosis such as blood viscosity
and total cholesterol (TC) were conﬁrmed by a stepwise
regression analysis for 21 items such as hemorheology and
bloodlipid[8].Correlationanalysisofbloodstasissyndrome
and pathological changes shown in coronary angiography
with coronary heart disease showed that the blood stasis
syndrome score was signiﬁcantly correlated to the maximal
stenosis degree and coronary lesion score demonstrated
by coronary angiography before percutaneous coronary
intervention (PCI), and the correlation was increased along
with the increasing of the patients’ age and the course of
the disease. Conclusions were also veriﬁed in our related
researches [9–11].
Through mathematical statistics method and computa-
tional intelligence approach, it was found out that the major
syndrome factors of coronary heart disease are blood stasis,
qi deﬁciency, turbid phlegm, qi stagnation, heat deposition,
yang deﬁciency, yin deﬁciency, and cold coagulation based
on calculation analysis of 5099 cases patients reported on
literatures and 1069 cases patients with coronary heart
disease validated by coronary angiographic. We also con-
structed the diagnosis scales of blood stasis syndrome and
its accompanied syndromes in coronary heart disease, such
as qi deﬁciency and blood stasis syndrome and qi stagnation
and blood stasis syndrome [12–14]. In the study of thera-
peutic evaluation system, taking coronary heart disease as
example, important indexes such as syndrome evaluation
scale, clinical critical events, and quality of life were selected
on the basis of completely evaluating the present indexes
through application of clinical epidemiology-/evidence-
based medicine method. Meanwhile, high validity and
reliability of therapeutic evaluation system of coronary heart
disease was constructed through comprehensive analysis of
various index by the hall for workshop of metasynthetic
engineering.ClinicaleﬃcacyscaleofTCMsyndromeandthe
primitive entry pool of scale for patient-reported outcomes
of coronary heart disease were established by our team
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2.2. Excavating the Classical Theory in TCM. It is meaningful
to promote the original innovation in integrative medicine
researches through further understanding the connotation
of syndrome diagnosis, therapeutic principle, and classical
prescription by modern science and technology. Among
these studies, three researches below are honored.
The ﬁrst one is blood stasis syndrome theory and the
clinical application of the method of promoting blood
circulationandremovingbloodstasis.Bloodstasissyndrome
theory is ﬁrst recorded in The Songs of Chu, a classical
literature written in ancient China. Shuo Wen Jie Zi (Text
Notes and Word Explanations) written by Xu Shen in
the Eastern Han Dynasty explained that blood stasis is
hematocele. And it was frequently mentioned in TCM
classics such as the Canon of Internal Medicine, Treatise on
Febrile Diseases,a n dSynopsis of Golden Chamber. Inspired
by the prominent TCM doctor Guo Shikui’s experience in
treating angina pectoris by Decoction for Removing Blood
Stasis, a classic formula developed by Wang Qingren in
Qing Dynasty, academician Chen Keji advocated treating
coronary heart disease by activating blood circulation to
dissipate blood stasis principally. His team was the ﬁrst to
study the diagnostic criteria of blood stasis syndrome and
report the quantitative scoring method, which had been
extensively used in domestic and was the ﬁrst study in using
objective quantitative method in TCM syndrome study.
Objectiﬁed study of abdomen diagnosis on blood stasis
syndrome was also superior to the researchmethods of Japan
in the same period. Standards of syndrome diﬀerentiation
and therapeutic evaluation of coronary heart disease were
formulated according to above-mentioned researches, which
had already become national standards. The essence of
blood stasis syndrome and mechanism of treating coronary
heart disease by activating blood circulation to dissipate
blood stasis had been elucidated at various levels of intact
animal, tissue, cell, molecule, and gene protein expression.
As coronary restenosis after coronary artery balloon injury
and stent placement have been considered an international
diﬃcult problem, academician Chen ﬁrstly treated it by
decoction for removing blood stasis and optimized the
prescription to a more simpliﬁed and eﬀective recipe, Xiong
Shao Capsule (XSC). A randomized controlled trial (RCT)
about XSC showed that the restenosis rate in XSC group
treated by XSC on the basis of routine western therapy was
decreased by 45% compared with routine western therapy
group, and the experimental studies showed that XSC could
suppress the gene expression of proliferation of vascular
smooth muscle cells [16–19]. With important academic
value and clinical signiﬁcance, the study has promoted the
academic development of TCM greatly, which had been
awarded the ﬁrst award of national science and technology
progress in 2003.
The second study is the theory of dispelling interior
pathogenic factors and purgation and its application in the
treatment of acute abdomen. According to the theoretical
basisof“thesixfu-viscerafunctionwellwhenunobstructed,”
academician Wu Xianzhong began to explore integrative
medicine therapy on acute abdomen in early years. Through
unifying standard for syndrome diﬀerentiation and deﬁning
operative indication, his team accumulated a large number
of valid acute abdomen cases with the therapeutic method
of expelling pathogens by purgation. Under the leader-
ship of Professor Wu, the multidisciplinary and prospec-
tive researches included the eﬀects of dispelling interior
pathogenic factors and purgation on the splanchnic blood
ﬂow and caecal single smooth muscle cell, the clinical char-
acteristics of multiple organ dysfunction syndrome (MODS)
caused by several diﬀerent kinds of elements, the changes
of nerve-endocrine-immunological network in MODS and
the eﬀects of purgative herbs on information transmission
mechanism of immune cells through four times of diﬀerent
scale joint research in the seventh to tenth ﬁve-year plan
period. After years of eﬀorts, signiﬁcant progress had been
made and the operation rate had been reduced in the
treatmentofacuteabdomen,suchassevereacutecholangitis,
acute severe pancreatitis, and complicated biliary stones,
which was awarded the second award of national science and
technology progress in 2003 [20–22].
The third one is the theory of “treating the toxifying
disease with poisonous agents” and researches for arsenic
trioxide (AS2O3) treating acute promyelocytic leukemia
(APL). The theory is a traditional simple understanding of
hypertoxic drug treating diﬃcult and complicated diseases.
It was recorded in Compendium of Materia Medica that the
herbal nature of arsenolite is very hot and poisonous, while
white arsenic sublimed from arsenolite is more poisonous.
White arsenic is a traditional external drug for removing
the necrotic tissue and promoting granulation plaster, the
eﬀective component of which is AS2O3. The research was
enlightened by the prominent TCM doctor’s experienced
external prescription for treating skin cancer. On the basis of
veriﬁcation of curative eﬀects and optimizing prescription,
researchers developed the arsenous acid injection from
the experienced external prescription, which had deﬁnitive
curative eﬀect for the patients with APL and reached the
t o pl e v e li nt h ew o r l d[ 23–26]. The mechanism of arsenous
acid treating APL was illustrated from the perspective of
molecular oncology, including degradation of PML/RARa
fusion proteins, downregulating gene expression of Bcl2 and
inducing apoptosis in leukemia cells. Arsenous acid became
the ﬁrst antileukemia drug of inducing apoptosis in the
world arousing the medical research fever of arsenic trioxide
[27–29]. It was honored as “ancient remedy performs new
tricks” in 1996 by Science [30]. Sloan-Kettering and his
coworkers reported that 12 patients with recurrence of APL
after conventional chemotherapies were treated with AS2O3,
and 11 cases of them relieved completely in 1996. This paper,
published in New England Journal of Medicine, directly led
to the widely acceptance of AS2O3 in the treatment of APL in
the international medical ﬁeld [31].
2.3. Preventing and Curing Refractory Diseases. As the fron-
tier ﬁeld and hot issue of cardiovascular diseases, restenosis
after percutaneous coronary intervention and myocardial
ischemia reperfusion injury (MIRI) during open heart
surgery of cardiopulmonary bypass has become the best
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Researches showed that restenosis after percutaneous coro-
nary intervention was closely related to blood stasis syn-
drome. Predominantly evaluated by restenosis (RS) rate
estimated by coronary angiography (CAG), a prospective
randomized controlled study was carried out on RS after
PCI to observe the intervention eﬀect of Xiong Shao Capsule
(XSC). Compared with the control group, the incidence of
RS rate in the XSC group was signiﬁcantly lower (24.1%
versus 48.5%, P<0.05) and the extent of angiostenosis and
diameter of the culprit arteries, determined by CAG, also
signiﬁcantly reduced after patients had been treated for 6
months with [(2.21 ± 0.85) mm versus (1.72 ± 0.99) mm,
P<0.05], and [(26.58 ± 20.72) % versus (41.19 ± 30.92) %,
P<0.05], respectively. The incidence of clinical end-point
event was signiﬁcantly lower in the XSC group than that
in the control group (11.7% versus 27.6%) and the P value
was close to statistical signiﬁcance (P = 0.051). Comparing
with the control group, the blood-stasis syndrome score in
the XSC group was also signiﬁcantly lower (P<0.01). The
results showed that XSC had a wide range of therapeutic
eﬀects including eﬀectively preventing RS after PCI in
combination with conventional western medical treatment,
decreasing the attack of angina pectoris and improving the
blood stasis syndrome. Experimental researches on blood
activating herbs showed that it can signiﬁcantly inhibit
pathological vascular remodeling after balloon injury, thus
reduce late lumen loss and prevent restenosis [32–36].
As the establishing the cardiopulmonary bypass of open
heartsurgeryis key point of successfuloperation, myocardial
ischemia reperfusion injury (MIRI), which is very obvious
during the recovery of circulation, has become the hot
issue needed to be resolved. Some scholars found that
the pathogenesis of MIRI during open heart surgery of
cardiopulmonarybypassisdeﬁciencyofheartqiintheorigin
and excess of heart blood stasis and internal turbid toxin in
the superﬁciality and the therapeutic principles are boosting
qi and nourishing heart, activating blood circulation and
resolving toxin simultaneously. It was proposed that of
astragalus injection and tetramethylpyrazine injection for
boosting qi and activating blood circulation should be given
by vein injection during operation and Hu Xin Bao (com-
patibility of extracts of ginseng and panax notoginseng with
taurine) for boosting qi, activating blood circulation, and
resolvingtoxin shouldbegiven byoraladministration before
operation. The research showed that astragalus injection
combined with tetramethylpyrazine injection could reduce
the content of MDA and myocardial enzymes’ release and
improve the activity of SOD, NO, and NOS. Serial studies
demonstrated that boosting qi combined with activating
blood circulation have signiﬁcantly synergetic eﬀects, and
boosting qi, activating blood circulation, combined with
resolving toxin were superior to those simple boosting qi,
activating blood circulation, resolving toxin, and boosting qi
combined with activating blood circulation [37, 38].
Multiple organ dysfunction syndrome (MODS) is one of
thediﬃcultproblemsintheﬁeldofthecriticalcaremedicine,
which is characterized by acute onset, rapid progress, and
extremely high mortality. Since the 1970s of 20th century,
some scholars began to take vigorous action to explore a
new way of preventing and treating MODS by integrative
medicine and a new theory of “bacteria and bacterial
toxin treatedsimultaneously” waspresented ultimately. They
also perfected schemes for the diagnosis procedure and
treatment standard of MODS by both TCM and integrative
medicine. And four therapeutic principles for the main types
of syndromes were put forward, such as activating blood
circulation to dissipate blood stasis therapy on blood stasis
syndrome, clearing heat and toxin therapy on heat toxin
syndrome, reinforcing the vital energy and consolidating
the constitution therapy on acute deﬁcient syndrome, and
dispelling interior pathogenic factors and purgation therapy
on Yangming fu-organ syndrome. Integrative medicine
therapy can eﬀectively improve the clinical eﬃcacy and
shorten the course of the disease thus reducing mortality.
A famous injection of Chinese medicine, “Shen Nong 33,”
with the eﬀect of activating blood circulation to dissipate
blood stasis and antiendotoxin, was developed, which has
reduced the mortality of international recognized infectious
four or more organs failure from 100% to 50% and reached
theinternationaladvancedlevel.Furthermore,anewstrategy
of “bacteria, bacterial toxin, and inﬂammatory mediator
treated simultaneously” was put forward on the basis of
the theory of “bacteria and bacterial toxin treated simulta-
neously.” Xue Bi Jing injection, the ﬁrst Chinese medicine
preparation in emergency medicine, was developed, which
have made great contributions to the advancement of critical
care medicine [39–43].
Chronic hepatitis B is the common disease in China, as
well as in the world, causing great aﬄiction to patients. It
has become the major issue in the treatment of chronic liver
disease. The progression of chronic hepatitis B may lead to
liver cirrhosis and hepatocellular carcinoma. Hepatic ﬁbrosis
is the common pathological end stage of various chronic
liver diseases regardless of the etiology, and blocking the
occurrenceanddevelopmentofﬁbrosisofliverisveryimpor-
tant in chronic hepatic diseases’ treatment and prognosis.
TCM has become the important therapy in treating chronic
hepatitis, liver ﬁbrosis, and liver cirrhosis. Some scholars
put forward the hypothesis that liver ﬁbrosis and early liver
cirrhosis can be reversed. They found out that the basic
pathogenesis of liver ﬁbrosis is weakened body resistance
and blood stasis, so therapeutic method of strengthening
body resistance and dispelling stasis was established, and
“Fu Zheng Hua Yu Capsules,” a new drug for treating liver
ﬁbrosis, was developed. Predominantly evaluated by liver
tissue ﬁbrosis, clinical researches were carried out to observe
thecurativeeﬀectofthetherapeuticmethodofstrengthening
body resistance and dispelling stasis. The total inversion
rate of liver tissue ﬁbrosis was 52% to 58.3% compared
before and after treatment, which also conﬁrmed that liver
ﬁbrosiscanbereversedandtreated.Themechanismincludes
signiﬁcantly inhibiting lipid peroxidation, the proliferation
of hepatic stellate cell and activation of collagen expression,
reducing inﬂammation of hepatocytic injury model, increas-
ing the activity of matrix metalloproteinases, promoting the
degradationofpathologicallivercollagen,andsoon[44–46].
Combining the macroscopic view with microscopic
view, syndrome diﬀerentiation with disease diﬀerentiation,Evidence-Based Complementary and Alternative Medicine 5
regional with global, taking stopgap measures with taking
radical measures, supporting healthy aspects with elimi-
nating pathogens, tumor treatment model by integrative
medicine emphasizes contriving individual treatment plan
and evaluation standard on the basis of biological charac-
teristics and the course of disease. Malignant tumors could
be treated by TCM therapies such as reinforcing the vital
energy and consolidating the constitution, supplementing
qi and nourishing yin, and clearing away heat and toxic
materials, combined with conventional therapies such as
radiotherapy, chemotherapy, and surgery. TCM treatment
hassigniﬁcancesindecreasingtoxicityandincreasingeﬃcacy
on radiotherapy and chemotherapy. Integrative medicine
theory has a remarkable eﬀect in alleviating symptoms such
as dry mouth in hyperpyrexic consumption of yin syndrome
and deﬁciency of both qi and yin syndrome caused by head
and neck cancer after radiotherapy, relieving symptoms such
as cough caused by acute radiation pneumonitis, improving
immune function, and survival quality of postoperative
patients, preventing the tumor from recurrenceor metastasis
and prolonging survival time. The new model of com-
bining TCM and modern cancer treatment has attracted
widespread attention in the world, which is known as
“China Model for Cancer Treatment” [47]. In addition,
screening of tumor inhibition from more than 3,000 species
of Chinese herbs and nearly 300 Chinese herbal compound,
eﬀective components having directly killing eﬀect on cancer
cell such as indirubin, camptothecin, vinblastine, matrine,
and aclitaxel were extracted. Some Chinese herbs, having
the eﬀect of immunological enhancement and biological
responsemodiﬁer-likeactionsuchaspolyporus,poriacocos,
and mushroom, were also found out.
APL is a special type of acute leukemic (AL). TCM
suggests that the pathogenesis of APL is weakened body
resistance and excessiveness of pathogen, so therapeutic
method of eliminating pathogenic factors and strengthening
body resistance was established. Some scholars developed
the Compound Realgar Natural Indigo Tablets (Realgar,
Indigo Naturals, Salvia and Radix pseudostell) on the basis
of clearing away heat and toxic materials and supplementing
qi with activating blood circulation and promoting hemo-
genesis method. 155 cases of APL patients were treated
by the Compound Realgar Natural Indigo Tablets and the
remission rate was 97.42% after treating for 6 months. No
side eﬀect, serious infection, bleeding, and DIC were found
during the treatment course. It was also characterized by
higher negative conversion rate of PML—RARα fusion gene
and simple application. The results demonstrated that the
complete remission rate of treatment of the Compound
RealgarNaturalIndigoTabletswere10–15%higherthanthat
of all-trans retinoic acid (ATRA). On this basis, the eﬀect
of post-remission therapy mainly with Compound Realgar
Natural Indigo Tablets on long-term survival of 74 cases
patients with APL showed that the median remission time
was48monthswithrecurrencerateonly14.86%and10-year
survival probability was 75.38% [48–50].
Since the 1970s of 20th century, the basic syndrome
of type 2 diabetes included yin deﬁciency with internal
excessive heat, deﬁciency of both qi and yin, and deﬁciency
of both yin and yang, therefore, III-type diﬀerentiation
of type 2 diabetes was established and developed. It had
already been adopted by national guidelines for new drug
in the late 1980s. As deﬁciency of both qi and yin was
the important basic syndrome of the disease, “Jiang Tang
Jia tablets,” a new Chinese herb of supplementing qi and
nourishing yin, could improve insulin resistance, islet β-
cell function, and the level of glucose and lipid metabolism,
the total eﬀective rate of which was 76.54%. In addition,
researches of Tang Wei Kang capsule treating early diabetic
nephropathyandTang Xin Ping treatingdiabeticcardiopathy
have gotten progress [51, 52]. Some scholars also found out
that blood stasis was another signiﬁcant pathogenesis of type
2 diabetes due to the changes of hemorheology with diﬀerent
degree were found. So they advocated treating the disease
by promoting blood circulation and removing blood stasis
principally. Based on this idea, promoting blood circulation
by removing blood stasis recipes, such as nourishing yin and
activating blood recipes and Xian Zhen tablet of reinforcing
kidney and activating blood, were developed. Those recipes
have multilevel and multitarget eﬀects, including improv-
ing symptoms, reducing blood glucose, improving blood
rheology and blood ﬂow, lowering triglycerides (TGs), and
malondialdehyde (MDA), enhancing activity of erythrocyte
SOD, Na+-K+-ATP enzyme and Ca2+-Mg2+-ATP enzyme,
and so forth. The experimental studies showed that the eﬀect
of Xian Zhen tablet includes lowering blood glucose and
glycosylatedhemoglobin,decreasingurineproteinexcretion,
improving renal function, reducing the pathological changes
ofglomerularmesangialexpansionandbasementmembrane
thickening, decreasing AGEs amounts of renal cortex, and
downregulating RAGE-mRNA expression in renal cortex
and endothelia of heart vessel. It provided a new idea
for preventing and treating diabetic and chronic vascular
complications [53, 54].
Severe pancreatitis, namely, acute hemorrhagic necro-
tizing pancreatitis, is characterized by acute onset, rapid
progress, high mortality, and poor prognosis. 65% of the
death cases are due to complicating with acute respiratory
distresssyndrome(ARDS).Accordingtothetheoreticalbasis
that “the six fu-viscera function well when unobstructed”
and “the lung and the large intestine are interior-exteriorly
related,” acute pancreatitis is treated by expelling pathogens
by purgation, and the average cure rate reached to 97%,
while the average cure rate of severe pancreatitis was 80%.
Compared with our country and abroad, the mortality
has reached the lowest level. Qing Yi decoction, a famous
antipyretic and purgative prescription, protected the lung
from injury in many aspects, by preserving the damage of
gut barrier function, reducing or eliminating endotoxemia
derived from the gut, inhibiting the production, and release
of TNF, IL-6, and the translocation of bacteria. The results
may fully show the superiority of integrative medicine in
treating serious diseases [55, 56].
A certain progress was also made on dermatosis and
burn medicine by integrative medicine therapy. Vitiligo was
eﬀectlytreatedbytakingmodiﬁedTao Hong Si Wu decoction,
external application of compound tar traditional Chinese
rubbing-drugs and melagenine extracted from placenta.6 Evidence-Based Complementary and Alternative Medicine
243 patients with vitiligo were treated by modiﬁed Tao Hong
Si Wu decoction and the total eﬀective rate was 68.2%,
the mechanism of which was related to upregulation of
tyrosinase activity, increasing the melagenine content, and
promoting melanocyte proliferation [57]. Moist exposed
burn therapy (MEBT), a new therapeutic system of burn
medicine in integrative medicine, has become the leading
enabler throughout the world. It is found out that the burn
wound should be kept in a moist but not macerated environ-
ment in order to promote in nature recovery and generation
of the skin rather than in traditional dry environment. And
the exact curative eﬀect was obtained by MEBT and moist
exposed burn ointment (MEBO) [58].
Severe acute respiratory syndrome (SARS) has aroused
international attention for strong infectiousness, rapid pro-
gression, poor prognosis, and high mortality, which has no
special eﬀective therapy yet. 524 patients of SARS in China
were divided into integrative medicine treatment group (n =
318) and western medicine treatment group (n = 206).
The existence rates for the symptoms of weakness, short
breath, dyspnea in the ﬁrst group were signiﬁcantly lower
than that in the second group after treatment. The duration
of weakness was averagely shortened by 1.5 days in the
ﬁrst group. And short breath, dyspnea, and muscle aching
pain were averagely shortened by 2 days, 1 day, and 2 days,
respectively. Researches showed that the eﬀect of integrated
therapy of TCM and WM for treating SARS was superior
to WM treatment alone, and the integrative medicine could
improve clinical symptoms such as weakness, short breath,
and dyspnea [59–61]. The exact clinical curative eﬀect was
also recognized by World Health Organization (WHO).
3.Developing Strategies
3.1. Standing on Frontier Field of International Medicine and
Improving the Capability of Preventing and Curing Refractory
Diseases. Previous achievements in clinical researches of
integrative medicine showed that it is absolutely necessary
to keep a foothold at frontier ﬁeld of international medicine
and life science and derive the wisdom and new theories
from these subjects in order to ﬁnd the innovation and
breakthrough from subject cross and osmosis. Aiming at
the hot issues and knotty problems confronted in clinical
medicine, we could put forward scientiﬁc hypotheses in
exploring the etiology and pathogenesis of the disease and
seek for the eﬀective therapeutic principles and classical
prescriptions. Basing on the research mentioned above, the
clinical eﬃcacy should be objectively evaluated by random-
ized controlled trials (RCT), and the potential mechanism
should be illustrated ultimately. By summarizing the clinical
regularity in time, it will contribute to the innovation of the
medical theory and guide clinical practice.
Taking coronary heart disease as example, despite great
advancements in the ﬁelds of basic and clinical researches
made by modern medicine, there are still some issues to be
resolved, such as acute coronary syndrome complicated by
microvascular thrombosis, myocardial ischemia-reperfusion
injury, no-reﬂow phenomenon, stent thrombosis, obvious
subjective symptoms such as hypodynamia and shortness of
breath remained after percutaneous coronary intervention
(PCI), and ventricular remodeling following myocardial
infarction [62–64]. Previous study showed that the prospects
of integrative medicine is brightening in treatment for
coronary stent thrombosis and protecting the myocardial
ischemia-reperfusion injury.
In addition, as viral infectious disease belonged to the
category of epidemic febrile disease in TCM thousands years
ago, Chinese ancients had accumulated rich experience and
formed a systematic and complete theory in treatment.
Currently, better therapeutic eﬃcacy of viral infectious
diseases could be achieved by combining two medical
systems, especially in SARS, N1H1, and bird ﬂu. Also, more
similar breakthrough points of integrative medicine can
be found, for instance, improving the low success rate of
assisted reproductive technology (ART) by combining ART
with TCM therapeutic method of reinforcing kidney and
activating blood, and so forth.
3.2. Moving Prevention and Control Strategy Forward and
Improving the Curative Eﬀect of Common and Frequent
Disease. “Moving prevention and control strategy forward”
is a national macrohealth policy, which well adapted to
the new medical model, “physiological-psychological-social-
environmental” model. It means that the focal point of
medicine will be transferred from treating disease to health
care, and disease prevention will be paid more attention to.
Therefore, the policy of “prevention ﬁrst” will be carried
out instead of traditional ideological concept “treatment is
more major than prevention.” It is similar to the TCM theory
of “preventive treatment of disease,” including principles
of “preventing measure taken before the occurrence of
disease” and “preventing measure taken after the occurrence
of disease” in Canon of Internal Medicine.C o n c r e t em e a -
sures of “moving prevention and control strategy forward”
include concept forward, funding forward, emphasis of the
researches forward, and measures to be carried out forward.
It could reduce the incidence of the major diseases from
the origin and eﬀectively control the medical expense and
save resources in medicine and health. Integrative medicine
researches should also observe the principles above and pay
more and more attention to improve the curative eﬀect of
common and frequent diseases.
Taking cardiovascular disease, for example, there are
about 30% of the population in the world died from
cardiovascular and cerebrovascular events, among which
62% of stroke and 49% of cardiovascular events were
directly caused by hypertension [65]. According to the
China cardiovascular reports (2008-2009), the occurrence
and mortality of cardiovascular disease is still increasing
in our country, and it is estimated that the number of
patients with cardiovascular disease is at least 230 million.
It also demonstrated that there were about 200 million
hypertensive patients in China with more than 10 million
patients increased annually. As the primary cardiovascular
riskfactor,therisklevelofhypertensionisequivalenttothree
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emphasis should be taken on prevention and intervention of
earlier-stage hypertension in clinical researches of integrative
medicine. Additionally, hyperlipidemia, hyperglycemia, obe-
sity,andotherriskfactorsalsoshouldbepaidmoreattention
to. It is reported by World Health Organization (WHO) that
if risk factors were controlled as early as possible, 80% of the
disease can be prevented eﬀe c t i v e l y ,s u c ha sc o r o n a r yh e a r t
disease, stroke, and diabetes. Furthermore, paying 1 yuan in
prevention will save 7-8 yuan in treatment.
3.3. Excavating the Classical Theory of TCM and Broadening
the Treatment System of Modern Medicine. JAMA, an inter-
national authoritative journal, have commented that tradi-
tional medicine should joint tracks with modern medicine.
It suggested that not only should we inherit traditional
academic thoughts but also keep an eye on modernization of
TCM and study it in a scientiﬁc and systematic way [66]. The
target is to fully digest the traditional Chinese medicine, and
apply it to modern medical system. How to do it? The ﬁrst
is further understanding of the essence in TCM, while giving
up the dross. The second is illustrating the mechanism of the
traditional therapy by using advanced scientiﬁc technology
in order to improve the safety of the treatment and alleviate
the toxicity adverse eﬀect.
Viscera, meridians, prescriptions, and syndromes, the
precious wealth in TCM left by our ancients, are worth
deeply researching into. However, as the theory is profound,
classical, and concise, combining with clinical practice is the
unique way to understand the connotation. For example, the
lung and the large intestine are interior-exteriorly related,
that is to say, the lung was associated with the large intestine
bymeridians.Intheclinicalpractice,dysfunctionofthelarge
intestine conduction could cause no descending of the lung
qi, conversely, no descending of the lung qi also can result
in obstruction of fu-qi. It is reported that introducing fu-
unblocking and purgation therapy into adults’ acute pneu-
monia is a rapid and eﬀective treatment. In the 70th of the
last century, Professor Wang had applied L i a n gG eS a n(Cool
Diaphragm Powder) to treat SIRS and MODS, which mainly
manifested as Yangming visceral substantive syndrome. The
result demonstrated that the respiratory function of 80%
patients with respiratory failure was rapidly improved, and
the recovery was greatly promoted. Among the patients with
acutepancreatitisaccompaniedwithMODS,thetherapyalso
received superior eﬃcacy. All of these theories mentioned
above, including blood stasis syndrome theory, theory of
dispelling interior pathogenic factors and purgation, and
theory of “treating the toxifying disease with poisonous
agents,” were all worth deeply excavated, which have being
greatlybroadenedthetreatmentsystemofmodernmedicine.
3.4. Improving the Innovation Level of New High Eﬀective
Drugs on the Basis of Classical Prescriptions and Herbs in
TCM. ComparedwithTCMtheory,Chineseherbsaremuch
easier to be modernized and recognized. Therefore, it is of
great signiﬁcance in promoting modernization, industrial-
ization, and industrialization of the Chinese herbs, by ways
of combining modern technology with fully understanding
of classical prescriptions and herbs.
China is a great power with rich herb resources. Accord-
ing to the records in Formula Dictionary of Traditional
Chinese Medicine, there are approximately 100 thousand
prescriptions, including special prescriptions and herbs for
certain diseases. The classical prescriptions and herbs pro-
vided with deﬁnite clinical indications are of more meaning
to be developed. That will provide an eﬀective shortcut to
improve the capability of developing new drugs, which is
characterized by deﬁnite chemical structure, explicit action
mechanism, obviously curative eﬀect, advanced formula-
tions, convenience for taking, and low price.
At present, the eﬀective fractions and monomers
extracted from Chinese herbs had obtained reliable clinical
beneﬁts. For instance, artemisinin extracted from Sweet
Wormwood (Artemisia annua L.) have a deﬁnite eﬀect in
the treatment of falciparum malaria, which had been con-
ﬁrmed by multinational joint researches. The new therapy
developed by Professor Tu Youyou has saved millions of lives
across the globe, especially in the developing world, which
had also been listed in the catalog of “essential medicines” by
the World Health Organization (WHO) [67–71]. Therefore,
Professor Tu was awarded the 2011 Lasker∼DeBakey Clinical
Medical Research Award for the discovering artemisinin
and its utility for treating malaria. The research will raise
a new global round of climaxes of modernization and
internationalization of TCM.
In addition, indirubin extracted from indigo naturals in
Danggui Long Hui Wan (Pill of Angelica sinensis, Gentian
and Aloe) could treat leukemia. Diterpenonid versicolaction
extracted from Tripterygium Wilfordii Hook can be used as
immunosuppressive agents for treating rheumatoid arthritis
(RA). Biphenyl dimethyl dicarboxylate (DDB) extracted
from Schisandra chinensis could decrease the ALT and AST
activity. Tetramethylpyrazine extracted from Ligusticum
ChuanxiongHorthasshowedagoodeﬀectforischemiccere-
brovascular disease. Cantharidin extracted from Mylabris
could treat liver cancer. Moreover, other active components
such as ginsenoside, total puerarin ﬂavonoids, polyporus
umbellate polysaccharides, ganoderma lucidum polysaccha-
ride,anisodamine,tanshinone,trichosanthin,tetrahydropal-
matine, tetrandrine, rubidate, ilexonin A, and ferulic acid
sodium.
3.5. Rerecognizing the Theory of Formula Corresponding
to Syndrome in TCM and Enhancing the Level of Clini-
cal Research Evidence Based on Evidence-Based Medicine.
Evidence-based medicine (EBM) is a new subject quickly
developed in the clinical medicine ﬁeld in the 1990s. The
core thinking is to combine evidence, personal experi-
ences, and patients’ actual situation to formulate scientiﬁc
measures for preventing diseases, promoting the recovery
and improving life quality. Among them, clinical evidence
originates mainly from randomized controlled trial (RCT),
systematic review, and meta-analysis. With medical science
transforming from traditional experience medicine into
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place in clinical medicine. Therefore, following the principle
of respecting science and evidence, it is of the utmost
importance to enhance the level of clinical research evidence
in TCM and integrative medicine [72–74].
It is noteworthy that the treatment concept, formula
corresponding to syndrome, lied in classical works of TCM,
is similar to the ideas of EBM. However, it had been ignored
for a long time. The theory of syndrome diﬀerentiation and
formula corresponding to syndrome are two characteristic
inheritance veins in TCM. Generally speaking, the former
is always the mainstream ideology in TCM, while the latter
has been paid little attention. Clinical medication based on
pathogenesis is the core idea of syndrome diﬀerentiation,
while clinical medication based on formula syndrome is
not exactly the same as it. The most signiﬁcant diﬀerence
between them is whether giving attention to the objective
evidences of formula utilization. The theory of formula
corresponding to syndrome attaches great importance to the
objective indications of herbs, which mainly comes from
long-term, large-scale and repeated clinical trials by Chinese
ancients.
As the indications of herbs are objective and concrete,
clinical eﬀect could be repeated at anytime, anywhere, and
for anybody. So it is suggested that, facing with one patient,
10 TCM physicians may prescribe the identical prescription
and get rapid treatment eﬀect simultaneously according
to the indications of formulae and herbs. This is just the
reason why the signiﬁcant curative eﬀect can be by classical
prescriptions get in treating severe and lingering illness. The
extractive process of indications is similar to the evidence-
based research, and indications of herbs have probably
exceeded the category of expert experience in EBM. There-
fore,carryingoutclinicalstudiesunderguidanceofEBMand
formula corresponding to syndrome is helpful to summarize
the indications of formulae and herbs, and enhance the level
of clinical research evidence in TCM [75–79].
4. Summary
The history of man’s science development showed that the
crossing and blending of two kinds of knowledge systems
will be able to set up a new knowledge system. Integrative
medicine, an unprecedented task in present world, is a new
pattern of medicine, which is formed by the integration of
TCMandWM.Thecurrentsituationofintegrative medicine
career was highly evaluated by academician Han Qide.
He pointed out that integrative medicine is an inevitable
choice for the development of Chinese medicine and the
breakthrough point of development for modern medicine,
which have unique advantages and will play an important
role in China. With changing of the disease chart, increasing
of metabolic disease, malignant tumor, iatrogenic disease
and drug-induced disease, and the coming of senile society
as well as the change of people’s views on health and medical
mode, both opportunities and challenges have been brought
tothedevelopmentofintegrativemedicine.Thuswebelieved
that under the guidance of “pay equal attention to both
WM and TCM” and “implementing the integrative medicine
and developing TCM,” integrative medicine will obtain great
achievements in creating new medicine and pharmacology,
whichbuildsonthecombinationofbothWMandTCM,and
make tremendous contributions for the great rejuvenation of
the Chinese nation and human health care [80].
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